CytomX Therapeutics (CTMX) Non-Current Deferred Tax Liability (2014 - 2018)

CytomX Therapeutics has reported Non-Current Deferred Tax Liability for 5 years, with the latest figure at $1.1 million in Q4 2018.

• For the quarter ending Q4 2018, Non-Current Deferred Tax Liability changed N/A year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2018 stood at $1.1 million (changed N/A YoY), and the FY2018 full-year result was $1.1 million, changed N/A from the prior year.
• Non-Current Deferred Tax Liability for Q4 2018 stood at $1.1 million, up from $520000.0 in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $1.1 million in Q4 2018, with the low at $499000.0 in Q4 2014.
• Historically, Non-Current Deferred Tax Liability has averaged $570181.8 across 5 years, with a median of $513000.0 in 2016.
• The largest YoY upside for Non-Current Deferred Tax Liability was 5.07% in 2017 against a maximum downside of 0.78% in 2017.
• CytomX Therapeutics' Non-Current Deferred Tax Liability stood at $499000.0 in 2014, then gained by 1.6% to $507000.0 in 2015, then climbed by 1.18% to $513000.0 in 2016, then increased by 1.36% to $520000.0 in 2017, then surged by 118.65% to $1.1 million in 2018.
• The last three Non-Current Deferred Tax Liability figures came in at $1.1 million (Q4 2018), $520000.0 (Q3 2017), and $539000.0 (Q2 2017), per Business Quant data.